New drug combo aims to lower liver vein pressure in cirrhosis patients

NCT ID NCT05282121

Terminated Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether the drug Avenciguat, taken alone or with empagliflozin, can lower high blood pressure in the portal vein (the main vessel to the liver) in people with cirrhosis. About 90 adults with cirrhosis from hepatitis or fatty liver disease were enrolled. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Avenciguat (BI 685509) and empagliflozin
What this could lead to: If it works, this could lead to a new treatment option to reduce dangerous pressure in the liver's main vein, potentially preventing complications in cirrhosis.
What could go wrong: This was a small, early-phase trial that was terminated, so results are limited. It is unclear if the drug will prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver liver disorder portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION, PORTAL LIVER DISEASES

Contacts and locations

Show contact details

Locations

AKH - Medical University of Vienna

Vienna, 1090, Austria
American Research Corporation

San Antonio, Texas, 78215, United States
Amsterdam UMC, location VUMC

Amsterdam, 1105 AZ, Netherlands
Azienda Ospedaliera Policlinico di Modena

Modena, 41124, Italy
Beijing Friendship Hospital

Beijing, 100050, China
California Liver Research Institute

Pasadena, California, 91105, United States
Centre Hospitalier de l'Universite de Montreal (CHUM)

Montreal, Quebec, H2X 0A9, Canada
Edegem - UNIV UZ Antwerpen

Edegem, 2650, Belgium
Floridian Clinical Research-Miami Lakes-68368

Miami Lakes, Florida, 33016, United States
HOP Beaujon

Clichy, 92118, France
HOP Rangueil

Toulouse, 31059, France
Hospital Britanico de Buenos Aires

CABA, 1280AEB, Argentina
Hospital Italiano de Buenos Aires

CABA, C1199ABB, Argentina
Hospital Ramón y Cajal

Madrid, 28034, Spain
Hospital Vall d'Hebron

Barcelona, 08035, Spain
Hvidovre Hospital

Hvidovre, 2650, Denmark
Inland Empire Clinical Trials, LLC

Rialto, California, 92377, United States
Medizinische Hochschule Hannover

Hanover, 30625, Germany
NanFang Hosptial

Guangzhou, 510515, China
National Hospital Organization Yokohama Medical Center

Kanagawa, Yokohama, 245-8575, Japan
Osaka Metropolitan University Hospital

Osaka, Osaka, 545-8586, Japan
Ospedale Civile di Baggiovara

Baggiovara (MO), 41126, Italy
Policlinico "Paolo Giaccone"

Palermo, 90127, Italy
Rambam Medical Center

Haifa, 31096, Israel
Regional Institute of Gastroenterology Hepatology "Prof. Dr. O. Fodor"

Cluj-Napoca, 400000, Romania
Singapore General Hospital

Singapore, 169608, Singapore
The Affiliated Hospital of Hangzhou Normal University

Hangzhou, 310015, China
Universitätsklinikum Münster

Münster, 48149, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Mainz, 55131, Germany
Western Galilee Hospital

Nahariya, 2210001, Israel
Zhongshan Hospital Affiliated to Fudan University

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.